Drugs / NTRA-9620
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02865122 | Mar 2017 → Mar 2018 | short bowel syndrome | Elgan Pharma Ltd. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTRA-9620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02865122 ↗ |
| Route | Oral | “NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day” NCT02865122 ↗ |